Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 75 publications
Optimizing Tarlatamab Delivery in Small Cell and Neuroendocrine Lung Cancer: Real-World Insights into Step-Up Dosing and Prophylactic Tocilizumab Use.
Journal: Clinical lung cancer
Published: September 21, 2025
NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING.
Journal: The Journal of clinical investigation
Published: August 01, 2024
Phase I/II trial of plinabulin in combination with nivolumab and ipilimumab in patients with recurrent small cell lung cancer (SCLC): Big ten cancer research consortium (BTCRC-LUN17-127) study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 21, 2024
Unveiling the Molecular Features of SCLC With a Clinical RNA Expression Panel.
Journal: JTO clinical and research reports
Published: March 29, 2024
Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299.
Journal: JTO clinical and research reports
Published: June 30, 2023
A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 18, 2023
Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation.
Journal: Journal of thoracic disease
Published: April 25, 2023
Early Adverse Event Derived Biomarkers in Predicting Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy.
Journal: Cancers
Published: March 09, 2023
Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data.
Journal: Cancers
Published: December 19, 2022
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.
Journal: Journal for immunotherapy of cancer
Published: September 03, 2022
Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer.
Journal: International journal of radiation oncology, biology, physics
Published: August 18, 2022
Last Updated: 09/26/2026